Summit Corporation plc Share Price London S.E.
Equities
GB00B02T3K57
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- GBX | - |
24/05 | Sector Update: Health Care Stocks Decline Late Friday Afternoon | MT |
24/05 | Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.86B 2.37B 197B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 11.86% |
Latest transcript on Summit Corporation plc
Managers | Title | Age | Since |
---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 52 | 11/20/11 |
Robert Duggan
CEO | Chief Executive Officer | 79 | 01/19/01 |
Director of Finance/CFO | 46 | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Duggan
CEO | Chief Executive Officer | 79 | 01/19/01 |
Robert Booth
BRD | Director/Board Member | 70 | 28/22/28 |
Director of Finance/CFO | 46 | 01/19/01 |
1st Jan change | Capi. | |
---|---|---|
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |